子素抑制NMDA受体的机制 - 与子素的比较
相关实验视频
Updated: May 24, 2025

05:42
The Forced Swim Test as a Model of Depressive-like Behavior
Published on: March 2, 2015
37.0K
Arseniy S Zhigulin1, Oleg I Barygin1
1I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry RAS, Saint-Petersburg, Russia.
European journal of pharmacology
|March 6, 2025
概括
一种新型抗抑郁药Vortioxetine在老鼠神经元中强烈抑制N-甲基-D-酸盐受体 (NMDARs),作用类似于fluoxetine. 这些发现表明,NMDARs是子和相关抗抑郁药的主要点.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- N-甲基-D-酸盐受体 (NMDARs) 在抑郁症的病理生理学中起着至关重要的作用.
- 许多抗抑郁药物通过抑制NMDARs来发挥其作用.
研究的目的:
- 研究一种多抗抑郁药 - - 伏尔西对原生NMDARs的作用.
- 为了比较vortioxetine的NMDAR抑制与结构相似的抗抑郁药物fluoxetine的抑制.
主要方法:
- 在大鼠海马的CA1金字塔神经元中,对原生NMDARs的电生理学记录.
- 评估vortioxetine和fluoxetine的抑制动力学,包括IC50值和电压依赖性.
- 对竞争性与非竞争性,电压依赖性与电压独立性抑制机制的分析.
主要成果:
- 西抑制了NMDARs,IC50为11±1μM在-80mV,显示出大约是西的三倍强度.
- 两种药物的抑制是非竞争性的,并表现出复杂的电压依赖性,包括电压依赖 (捕捉区块) 和电压独立 (全质) 组件.
- 西和西都可以抑制开放和关闭的NMDAR通道.
结论:
- N-甲基-D-阿斯巴甜酸盐受体可能是子素的重要分子标.
- 西和西之间的结构相似性表明,它们可能除了血清素载体和NMDAR之外还有其他分子点.
- 这些发现有助于理解新型抗抑郁药的作用机制,如伏尔西丁.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
175
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
175
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
271
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
271
Drugs Affecting Neurotransmitter Release or Uptake
917
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
917
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.1K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
209
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
209
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
67
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
67

